{"id":3988,"date":"2017-08-13T07:38:59","date_gmt":"2017-08-13T07:38:59","guid":{"rendered":"https:\/\/andromedichyperthermia.com\/andromedic-esho-2014\/"},"modified":"2026-01-19T11:06:53","modified_gmt":"2026-01-19T11:06:53","slug":"andromedic-esho-2014","status":"publish","type":"page","link":"https:\/\/andromedichyperthermia.com\/de\/andromedic-esho-2014\/","title":{"rendered":"Andromedic ESHO 2014"},"content":{"rendered":"<p><script type=\"application\/ld+json\">\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@graph\": [\n    {\n      \"@type\": \"MedicalWebPage\",\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/de\/andromedic-esho-2014\/#webpage\",\n      \"url\": \"https:\/\/andromedichyperthermia.com\/de\/andromedic-esho-2014\/\",\n      \"name\": \"Klinische Studien mit Andromedic HyDeep 600 WM - ESHO-Kongress\",\n      \"isPartOf\": { \"@id\": \"https:\/\/andromedichyperthermia.com\/de\/#website\" },\n      \"inLanguage\": \"de-DE\",\n      \"mainEntity\": { \"@id\": \"https:\/\/andromedichyperthermia.com\/#hydeep-600wm\" },\n      \"about\": [\n        {\n          \"@type\": \"MedicalStudy\",\n          \"name\": \"LACC Zervixkarzinom-Studie\",\n          \"description\": \"Studie an 8 Patienten, die eine 100%ige lokale Kontrolle unter Verwendung von HyDeep 600 WM und HDR-Brachytherapie zeigt.\",\n          \"studySubject\": { \"@type\": \"MedicalCondition\", \"name\": \"Zervixkarzinom\" }\n        },\n        {\n          \"@type\": \"MedicalStudy\",\n          \"name\": \"Spanische Fall-Kontroll-Studie\",\n          \"description\": \"Gro\u00df angelegte Machbarkeitsstudie mit 293 Patienten an 9 Tumorlokalisationen.\",\n          \"sampleSize\": 293,\n          \"studyStatus\": \"Published\"\n        }\n      ],\n      \"mentions\": [\n        { \"@id\": \"https:\/\/andromedichyperthermia.com\/de\/hyperthermiearzt-salvatore-conte\/#person\" },\n        { \"@id\": \"https:\/\/andromedichyperthermia.com\/#organization\" }\n      ]\n    }\n  ]\n}\n<\/script><\/p>\n<div style=\"line-height: 1.6; color: #333; max-width: 1100px; margin: auto; font-family: 'Segoe UI', Helvetica, sans-serif; background-color: #fff; padding: 20px;\">\n<header style=\"border-bottom: 4px solid #1a2a6c; padding-bottom: 25px; margin-bottom: 40px; text-align: center;\">\n<h1 style=\"color: #1a2a6c; font-size: 28px; font-weight: 800; text-transform: uppercase; margin-bottom: 10px;\">European Society for Hyperthermic Oncology: ESHO 2014<\/h1>\n<h2 style=\"color: #b21f1f; font-size: 20px; font-weight: 600;\">Andromedic Intervention \u2013 Dr. Salvatore Conte<\/h2>\n<p style=\"font-size: 16px; max-width: 850px; margin: 15px auto; color: #555;\">Auf der <a href=\"http:\/\/esho.info\" target=\"_blank\" rel=\"noopener\">ESHO 2014<\/a> verk\u00fcndete <a href=\"\/de\/hyperthermiearzt-salvatore-conte\/\"><strong>Salvatore Conte, M.Sc.<\/strong><\/a> einen bedeutenden Meilenstein f\u00fcr das Andromedic-Hyperthermie-Team: die erfolgreiche Herstellung und Auslieferung von 25 <a href=\"\/de\/hydeep-600-wm-hyperthermie-gerat\/\"><strong>HyDeep 600 WM<\/strong> Tiefenlokalhyperthermie-Systemen<\/a> innerhalb von nur 18 Monaten, wobei weitere 40 Einheiten f\u00fcr den indischen Markt bestimmt sind.<\/p>\n<\/header>\n<div style=\"margin-bottom: 50px; border-radius: 15px; overflow: hidden; box-shadow: 0 10px 25px rgba(0,0,0,0.2);\">\n<p><iframe loading=\"lazy\" title=\"intervento Andromedic   Esho 20014\" width=\"640\" height=\"360\" src=\"https:\/\/www.youtube.com\/embed\/fgMdXxoJ1cI?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<\/div>\n<h2 style=\"text-align: center; color: #1a2a6c; margin-bottom: 30px; text-transform: uppercase;\">Pr\u00e4sentierte klinische Studien: HyDeep 600 WM Fortschrittliche onkologische Hyperthermie<\/h2>\n<section style=\"margin-bottom: 50px; border: 1px solid #e1e8ed; border-radius: 15px; overflow: hidden; box-shadow: 0 5px 15px rgba(0,0,0,0.05);\">\n<div style=\"background: #1a2a6c; color: #fff; padding: 20px;\">\n<h3 style=\"margin: 0; font-size: 19px;\">1. Radiochemotherapie + Hyperthermie + HDR-Brachytherapie bei LACC<\/h3>\n<\/div>\n<div style=\"padding: 30px; background: #f9f9f9;\">\n<p><strong>ZIELE:<\/strong> Untersuchung der Ergebnisse einer Kombination aus w\u00f6chentlichem Cisplatin und lokaler Tiefenhyperthermie mit IMRT, gefolgt von Brachytherapie (BRT) bei lokal fortgeschrittenem Zervixkarzinom (LACC).<\/p>\n<div style=\"background: #fff; padding: 20px; border-radius: 10px; margin: 20px 0; border-left: 5px solid #b21f1f;\">\n<p><strong>MATERIAL UND METHODIK:<\/strong><\/p>\n<ul style=\"margin-top: 10px; font-size: 15px;\">\n<li><strong>Patientengruppe:<\/strong> 8 Patientinnen (3 Stadium IIB, 1 IIIB, 2 NEI, 3 LRCC).<\/li>\n<li><strong>Protokoll:<\/strong> 50,4 Gy auf die Beckenlymphknoten mit SIB auf das GTV (insgesamt 61,8 Gy) in 28 Fraktionen. BRT-Dosis: 21 Gy in 3 Fraktionen.<\/li>\n<li><strong>Begleittherapie:<\/strong> W\u00f6chentlich Cisplatin 40mg\/m\u00b2 + HT einmal pro Woche.<\/li>\n<\/ul>\n<\/div>\n<div style=\"background: #e8f5e9; padding: 20px; border-radius: 10px; border: 1px solid #2e7d32;\">\n<p><strong style=\"color: #1b5e20; font-size: 17px; display: block; margin-bottom: 10px;\">ERGEBNISSE &amp; SCHLUSSFOLGERUNGEN:<\/strong><\/p>\n<p style=\"font-size: 16px; font-weight: bold; margin: 0;\">100% LOKALE KONTROLLE ERREICHT. Es wurde keine behandlungsbedingte akute oder sp\u00e4te Toxizit\u00e4t des Grades 3 bis 4 beobachtet.<\/p>\n<p style=\"margin-top: 10px; font-style: italic;\">&#8222;Die Erg\u00e4nzung der Radiochemotherapie durch lokale Tiefenhyperthermie stellt eine vielversprechende neue Strategie mit exzellenter Vertr\u00e4glichkeit dar.&#8220;<\/p>\n<\/div>\n<\/div>\n<\/section>\n<section style=\"margin-bottom: 50px; border: 1px solid #e1e8ed; border-radius: 15px; overflow: hidden; box-shadow: 0 5px 15px rgba(0,0,0,0.05);\">\n<div style=\"background: #b21f1f; color: #fff; padding: 20px;\">\n<h3 style=\"margin: 0; font-size: 19px;\">2. Quasi-Machbarkeitsstudie (Fall-Kontroll-Studie) \u2013 lokale Tiefenhyperthermie &#8211; Andalusien, Spanien<\/h3>\n<\/div>\n<div style=\"padding: 30px;\">\n<p><strong>Einf\u00fchrung:<\/strong> Die erste klinische Studie in Spanien, welche die lokale Tiefenhyperthermie mit Standard-Krebstherapien innerhalb des \u00f6ffentlichen Gesundheitssystems kombiniert.<\/p>\n<div style=\"display: grid; grid-template-columns: repeat(auto-fit, minmax(250px, 1fr)); gap: 20px; margin: 25px 0;\">\n<div style=\"background: #f0f4f8; padding: 15px; border-radius: 10px; border-top: 4px solid #1a2a6c;\"><strong>Studiendesign:<\/strong> Prospektive Fall-Kontroll-Studie. Insgesamt 293 Patienten (97 in der aktiven Phase vs. 196 Kontrollen). 9 Tumorentit\u00e4ten.<\/div>\n<div style=\"background: #f0f4f8; padding: 15px; border-radius: 10px; border-top: 4px solid #1a2a6c;\"><strong>Behandlungsparameter:<\/strong> 10 Sitzungen (2-3\/Woche), 1 Stunde Dauer, 150W\u2013400W unter Verwendung des <strong>HyDeep 600WM modulierten Hyperthermie-Systems<\/strong>.<\/div>\n<\/div>\n<h4 style=\"color: #1a2a6c; border-bottom: 2px solid #b21f1f; display: inline-block; padding-bottom: 5px;\">Vorl\u00e4ufige Daten (Sub-Kohorte von 22 Patienten):<\/h4>\n<ul style=\"margin-top: 15px; font-size: 14px; column-count: 2;\">\n<li><strong>Glioblastom (2c)<\/strong><\/li>\n<li><strong>Kopf-Hals-Tumoren (7c)<\/strong><\/li>\n<li><strong>Pr\u00e4operatives Rektum (3c)<\/strong><\/li>\n<li><strong>Mammakarzinom (3c)<\/strong><\/li>\n<li><strong>Lungenkrebs (NSCLC &#8211; 11c)<\/strong><\/li>\n<li><strong>Prostata (4c)<\/strong><\/li>\n<li><strong>Zervix &amp; Metastasen<\/strong><\/li>\n<\/ul>\n<div style=\"display: flex; flex-wrap: wrap; gap: 15px; margin: 25px 0;\">\n<div style=\"flex: 1; min-width: 200px; background: #fffde7; padding: 20px; border-radius: 10px; text-align: center; border: 1px solid #fbc02d;\"><span style=\"font-size: 28px; font-weight: 800; display: block;\">81,2%<\/span><br \/>\n<strong>HOHE TOLERANZ<\/strong><br \/>\n<small>Patienten zufrieden oder sehr zufrieden<\/small><\/div>\n<div style=\"flex: 1; min-width: 200px; background: #f1f8e9; padding: 20px; border-radius: 10px; text-align: center; border: 1px solid #7cb342;\"><span style=\"font-size: 28px; font-weight: 800; display: block;\">66,6%<\/span><br \/>\n<strong>KEINE TOXIZIT\u00c4T<\/strong><br \/>\n<small>Keine unerw\u00fcnschten Wirkungen gemeldet<\/small><\/div>\n<\/div>\n<p style=\"background: #f4f7f9; padding: 15px; border-radius: 8px; border-left: 4px solid #1a2a6c;\"><strong>FAZIT:<\/strong> Die lokale Tiefenhyperthermie ist in der klinischen Routine \u00f6ffentlicher Krankenh\u00e4user ohne au\u00dfergew\u00f6hnliche Ressourcen durchf\u00fchrbar. Eine sorgf\u00e4ltige Patientenauswahl gew\u00e4hrleistet eine minimale Toxizit\u00e4t (Grad 1).<\/p>\n<div style=\"text-align: center; margin-top: 30px;\"><a style=\"display: inline-block; background: #b21f1f; color: #fff; padding: 14px 30px; text-decoration: none; border-radius: 5px; font-weight: 800; text-transform: uppercase; box-shadow: 0 4px 10px rgba(178,31,31,0.3);\" href=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/Protocolo-del-ensayo-MAG-HIP-2013-01-11-EN.pdf\">Vollst\u00e4ndiges Studienprotokoll herunterladen (PDF)<\/a><\/div>\n<\/div>\n<\/section>\n<div style=\"margin-top: 40px;\">\n<h3 style=\"text-align: center; color: #1a2a6c; text-transform: uppercase; letter-spacing: 1px;\">ESHO Wissenschaftliche Poster &amp; Dokumentation<\/h3>\n<div id='gallery-1' class='gallery galleryid-3988 gallery-columns-1 gallery-size-full'><figure class='gallery-item'>\n\t\t\t<div class='gallery-icon portrait'>\n\t\t\t\t<a href=\"https:\/\/andromedichyperthermia.com\/de\/preliminary-results-of-chemoradiation-plus-hyperthermia-and-high-dose-rate-brachytherapy-for-locally-advanced-cervical-carcinoma-2\/\"><img loading=\"lazy\" decoding=\"async\" width=\"590\" height=\"837\" src=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/Preliminary-results-of-chemoradiation-plus-hyperthermia-and-high-dose-rate-brachytherapy-for-locally-advanced-cervical-carcinoma.jpg\" class=\"attachment-full size-full\" alt=\"\" aria-describedby=\"gallery-1-1330\" srcset=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/Preliminary-results-of-chemoradiation-plus-hyperthermia-and-high-dose-rate-brachytherapy-for-locally-advanced-cervical-carcinoma.jpg 590w, https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/Preliminary-results-of-chemoradiation-plus-hyperthermia-and-high-dose-rate-brachytherapy-for-locally-advanced-cervical-carcinoma-211x300.jpg 211w\" sizes=\"auto, (max-width: 590px) 100vw, 590px\" title=\"\"><\/a>\n\t\t\t<\/div>\n\t\t\t\t<figcaption class='wp-caption-text gallery-caption' id='gallery-1-1330'>\n\t\t\t\tPreliminary results of chemoradiation plus Andromedic hyperthermia and high dose rate brachytherapy for locally advanced cervical carcinoma\n\t\t\t\t<\/figcaption><\/figure><figure class='gallery-item'>\n\t\t\t<div class='gallery-icon portrait'>\n\t\t\t\t<a href=\"https:\/\/andromedichyperthermia.com\/de\/quasi-feasibility-studycase-control-asscoaiting-deep-local-hyperthermia-treatment-with-standard-cancer-treatments-and-describing-patterns-of-response-b-2\/\"><img loading=\"lazy\" decoding=\"async\" width=\"569\" height=\"831\" src=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/Quasi-feasibility-studycase-control-asscoaiting-deep-local-hyperthermia-treatment-with-standard-cancer-treatments-and-describing-patterns-of-response-B.jpg\" class=\"attachment-full size-full\" alt=\"\" aria-describedby=\"gallery-1-1309\" srcset=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/Quasi-feasibility-studycase-control-asscoaiting-deep-local-hyperthermia-treatment-with-standard-cancer-treatments-and-describing-patterns-of-response-B.jpg 569w, https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/Quasi-feasibility-studycase-control-asscoaiting-deep-local-hyperthermia-treatment-with-standard-cancer-treatments-and-describing-patterns-of-response-B-205x300.jpg 205w\" sizes=\"auto, (max-width: 569px) 100vw, 569px\" title=\"\"><\/a>\n\t\t\t<\/div>\n\t\t\t\t<figcaption class='wp-caption-text gallery-caption' id='gallery-1-1309'>\n\t\t\t\tQuasi feasibility study(case control) asscoaiting deep local hyperthermia treatment with standard cancer treatments and describing patterns of response ESHO\n\t\t\t\t<\/figcaption><\/figure><figure class='gallery-item'>\n\t\t\t<div class='gallery-icon portrait'>\n\t\t\t\t<a href=\"https:\/\/andromedichyperthermia.com\/de\/quasi-feasibility-studycase-control-asscoaiting-deep-local-hyperthermia-treatment-with-standard-cancer-treatments-and-describing-patterns-of-response-2\/\"><img loading=\"lazy\" decoding=\"async\" width=\"568\" height=\"826\" src=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/Quasi-feasibility-studycase-control-asscoaiting-deep-local-hyperthermia-treatment-with-standard-cancer-treatments-and-describing-patterns-of-response.jpg\" class=\"attachment-full size-full\" alt=\"\" aria-describedby=\"gallery-1-1288\" srcset=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/Quasi-feasibility-studycase-control-asscoaiting-deep-local-hyperthermia-treatment-with-standard-cancer-treatments-and-describing-patterns-of-response.jpg 568w, https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/Quasi-feasibility-studycase-control-asscoaiting-deep-local-hyperthermia-treatment-with-standard-cancer-treatments-and-describing-patterns-of-response-206x300.jpg 206w\" sizes=\"auto, (max-width: 568px) 100vw, 568px\" title=\"\"><\/a>\n\t\t\t<\/div>\n\t\t\t\t<figcaption class='wp-caption-text gallery-caption' id='gallery-1-1288'>\n\t\t\t\tQuasi feasibility study(case control) asscoaiting deep local hyperthermia HyDeep 600WM treatment with standard cancer treatments and describing patterns of response\n\t\t\t\t<\/figcaption><\/figure>\n\t\t<\/div>\n\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>European Society for Hyperthermic Oncology: ESHO 2014 Andromedic Intervention \u2013 Dr. Salvatore Conte Auf der ESHO 2014 verk\u00fcndete Salvatore Conte, M.Sc. einen bedeutenden Meilenstein f\u00fcr das Andromedic-Hyperthermie-Team: die erfolgreiche Herstellung und Auslieferung von 25 HyDeep 600 WM Tiefenlokalhyperthermie-Systemen innerhalb von nur 18 Monaten, wobei weitere 40 Einheiten f\u00fcr den indischen Markt bestimmt sind. Pr\u00e4sentierte klinische&hellip;<\/p>\n","protected":false},"author":1,"featured_media":17342,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"template-gutentor-full-width.php","meta":{"footnotes":""},"class_list":["post-3988","page","type-page","status-publish","has-post-thumbnail","hentry"],"_links":{"self":[{"href":"https:\/\/andromedichyperthermia.com\/de\/wp-json\/wp\/v2\/pages\/3988","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/andromedichyperthermia.com\/de\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/andromedichyperthermia.com\/de\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/de\/wp-json\/wp\/v2\/comments?post=3988"}],"version-history":[{"count":0,"href":"https:\/\/andromedichyperthermia.com\/de\/wp-json\/wp\/v2\/pages\/3988\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/de\/wp-json\/wp\/v2\/media\/17342"}],"wp:attachment":[{"href":"https:\/\/andromedichyperthermia.com\/de\/wp-json\/wp\/v2\/media?parent=3988"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}